policy
Regenerative medicine, including therapeutic use of stem cells
Regenerative medicine holds promise in treating a variety of diseases, yet questions remain. The AVMA supports the continued scientific development of…
policy
Guidelines for use of autogenous biologics
Autogenous biological products may provide veterinarians a unique opportunity for control of certain infectious diseases when USDA-licensed commercial…
policy
Guidelines for use of exempt biologics
State-licensed veterinarians may consider preparing biologics in their practice facility under a VCPR in unique disease situations not adequately…
policy
Development of emerging disease agent biologics
Development of emerging infectious disease biologics is essential for One Health. The AVMA supports the development of these products through…
JAVMA news
The risky business of global animal movement
Likely sources of another pandemic are being scrutinized like never before, including the global movement of animals via international trade and…
AVMA news
Advances in animal genome editing continue apace
The Food and Drug Administration (FDA) recently green lit for human consumption five genetically modified pigs at Washington State University.…
AVMA news
Conference of Research Workers in Animal Diseases – January 20-24, 2023
The Conference of Research Workers in Animal Diseases (CRWAD) held its annual conference from January 20-24 in Chicago. The CRWAD presented awards,…
AVMA news
USDA starts highly pathogenic avian influenza vaccine trials
In April, the U.S. Department of Agriculture (USDA) began testing the efficacy of four vaccines against highly pathogenic avian influenza (HPAI).…
policy
Joint AVMA-FVE-CVMA statement on the benefits of animal vaccination programs in advancing animal and human health
This statement has been adopted jointly by the AVMA, Federation of Veterinarians of Europe and Canadian Veterinary Medical Association.